The Claim

In adults with type 2 diabetes initiating pharmacotherapy, initiation of GLP-1 receptor agonists is associated with a significantly greater increase in pharmacy costs during the first year compared to initiation of SGLT-2 inhibitors or DPP-4 inhibitors, with no reduction in medical costs observed over two years.

Source: Healthcare Cost Trends in New Users of SGLT-2i, DPP-4i and GLP-1 RA for Type 2 Diabetes: An Observational Longitudinal Study.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
58score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Adults with type 2 diabetes who start GLP-1 receptor agonists pay more for their medications in the first year than those who start SGLT-2 inhibitors or DPP-4 inhibitors, and this higher cost is not offset by lower spending on other medical services over two years.

See the scientific wording

In adults with type 2 diabetes initiating pharmacotherapy, those starting GLP-1 receptor agonists experience a significantly greater increase in pharmacy costs during the first year compared to those starting SGLT-2 inhibitors or DPP-4 inhibitors, with no corresponding reduction in medical costs over two years, suggesting that higher drug acquisition costs are not offset by decreased utilization of other healthcare services.

Why this might work

GLP-1 receptor agonists are biologic drugs that require injection and are more expensive to produce than oral pills. They are prescribed at higher doses and more frequent intervals because they act more powerfully on blood sugar control, leading to higher pharmacy costs. These drugs do not reduce the need for other medical services like doctor visits or hospital stays because they do not reverse underlying tissue damage or eliminate complications.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Healthcare Cost Trends in New Users of SGLT-2i, DPP-4i and GLP-1 RA for Type 2 Diabetes: An Observational Longitudinal Study.

    People with type 2 diabetes who start GLP-1 drugs pay more for their prescriptions in the first year than those who start other pills, and they don’t save money on doctor visits or hospital stays to make up for it. The study confirms this pattern.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.